bioMérieux S.A
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more
Market Cap & Net Worth: bioMérieux S.A (BMXMF)
bioMérieux S.A (PINK:BMXMF) has a market capitalization of $14.81 Billion ($14.81 Billion) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #2572 globally and #1802 in its home market, demonstrating a -0.45% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying bioMérieux S.A's stock price $125.44 by its total outstanding shares 118067205 (118.07 Million).
bioMérieux S.A Market Cap History: 2015 to 2025
bioMérieux S.A's market capitalization history from 2015 to 2025. Data shows growth from $4.38 Billion to $14.81 Billion (14.08% CAGR).
bioMérieux S.A Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how bioMérieux S.A's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
3.07x
bioMérieux S.A's market cap is 3.07 times its annual revenue
0.69x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
28.29x
bioMérieux S.A's market cap is 28.29 times its annual earnings
363.13x
Lower than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $4.38 Billion | $1.96 Billion | $110.50 Million | 2.23x | 39.62x |
| 2016 | $5.45 Billion | $2.10 Billion | $179.10 Million | 2.59x | 30.46x |
| 2017 | $9.91 Billion | $2.29 Billion | $238.10 Million | 4.33x | 41.62x |
| 2018 | $7.37 Billion | $2.42 Billion | $256.50 Million | 3.04x | 28.74x |
| 2019 | $10.14 Billion | $2.67 Billion | $272.80 Million | 3.79x | 37.17x |
| 2020 | $15.77 Billion | $3.12 Billion | $404.40 Million | 5.06x | 39.00x |
| 2021 | $16.09 Billion | $3.38 Billion | $601.10 Million | 4.77x | 26.77x |
| 2022 | $12.29 Billion | $3.59 Billion | $452.40 Million | 3.42x | 27.17x |
| 2023 | $12.70 Billion | $3.67 Billion | $357.60 Million | 3.45x | 35.50x |
| 2024 | $12.23 Billion | $3.98 Billion | $432.20 Million | 3.07x | 28.29x |
Competitor Companies of BMXMF by Market Capitalization
Companies near bioMérieux S.A in the global market cap rankings as of March 18, 2026.
Key companies related to bioMérieux S.A by market ranking:
- Thermo Fisher Scientific Inc (NYSE:TMO): Ranked #90 globally with a market cap of $177.20 Billion USD.
- Danaher Corporation (NYSE:DHR): Ranked #151 globally with a market cap of $122.79 Billion USD.
- IDEXX Laboratories Inc (NASDAQ:IDXX): Ranked #466 globally with a market cap of $46.38 Billion USD.
- Lonza Group Ltd (PINK:LZAGF): Ranked #511 globally with a market cap of $41.73 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #90 | Thermo Fisher Scientific Inc | NYSE:TMO | $177.20 Billion | $472.71 |
| #151 | Danaher Corporation | NYSE:DHR | $122.79 Billion | $195.21 |
| #466 | IDEXX Laboratories Inc | NASDAQ:IDXX | $46.38 Billion | $586.98 |
| #511 | Lonza Group Ltd | PINK:LZAGF | $41.73 Billion | $596.13 |
bioMérieux S.A Historical Marketcap From 2015 to 2025
Between 2015 and today, bioMérieux S.A's market cap moved from $4.38 Billion to $ 14.81 Billion, with a yearly change of 14.08%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $14.81 Billion | +21.12% |
| 2024 | $12.23 Billion | -3.69% |
| 2023 | $12.70 Billion | +3.29% |
| 2022 | $12.29 Billion | -23.61% |
| 2021 | $16.09 Billion | +2.03% |
| 2020 | $15.77 Billion | +55.54% |
| 2019 | $10.14 Billion | +37.51% |
| 2018 | $7.37 Billion | -25.60% |
| 2017 | $9.91 Billion | +81.68% |
| 2016 | $5.45 Billion | +24.60% |
| 2015 | $4.38 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of bioMérieux S.A was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $14.81 Billion USD |
| MoneyControl | $14.81 Billion USD |
| MarketWatch | $14.81 Billion USD |
| marketcap.company | $14.81 Billion USD |
| Reuters | $14.81 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.